Filing Flows › Arbutus Biopharma (ABUS) › Q1 2025
Arbutus Biopharma (ABUS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Arbutus Biopharma (ABUS) reported revenue of $1.8M for the first quarter 2025 (Q1 2025), +15% from a year earlier and +12% from the quarter before.
Arbutus Biopharma, Q1 2025: revenue $1.8M (+15% year over year), net loss $24.5M, operating cash flow −$13.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | +12% | +15% |
| Operating profit | −$25.7M | — | — |
| Net earnings | −$24.5M | — | — |
| Operating cash flow | −$13.4M | — | — |
What changed
Revenue was $1.8M in Q1 2025, up 15% year over year and up 12% from the previous quarter. Collaborations and licenses was the largest line at 75% of revenue. Collaborations and licenses added $377K year over year (up 40%), 162% of the total change. Non-cash royalty revenue declined 24%.
Operating costs exceeded revenue by $25.7M, an operating margin of -1456.9%. Total costs grew 31% against revenue growth of 15%. The fastest-growing cost line was Other operating costs (+6940%). The quarter ended with a net loss of $24.5M, wider than the previous quarter's $12.5M loss.
Operating cash flow was −$13.4M. Non-cash charges added back $330K of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items added $7.2M.
Questions
What was Arbutus Biopharma's revenue in the first quarter 2025?
Arbutus Biopharma (ABUS) reported revenue of $1.8M for the first quarter 2025 (Q1 2025), +15% from a year earlier and +12% from the quarter before.
Source: Arbutus Biopharma 10-Q on SEC EDGAR.